The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ACELYRIN INC | COM | 00445A100 | 80,616,107 | 3,857,230 | SH | SOLE | 3,857,230 | 0 | 0 | |||
| ALX ONCOLOGY HLDGS INC | COM | 00166B105 | 72,846,437 | 9,699,925 | SH | SOLE | 9,699,925 | 0 | 0 | |||
| ELEVATION ONCOLOGY INC | COM | 28623U101 | 4,429,668 | 2,914,255 | SH | SOLE | 2,914,255 | 0 | 0 | |||
| HARMONY BIOSCIENCES HLDGS IN | COM | 413197104 | 36,435,585 | 1,035,396 | SH | SOLE | 1,035,396 | 0 | 0 | |||
| IMPEL PHARMACEUTICALS INC | COM | 45258K109 | 3,504,935 | 2,759,791 | SH | SOLE | 2,759,791 | 0 | 0 | |||
| PHARVARIS N V | COM | N69605108 | 64,567,134 | 4,264,672 | SH | SOLE | 4,264,672 | 0 | 0 | |||
| VENTYX BIOSCIENCES INC | COM | 92332V107 | 13,908,250 | 424,032 | SH | SOLE | 424,032 | 0 | 0 | |||